Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis
- Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis
- 조현종; 윤홍열; 구희범; 고성학; 심재성; 조희현; 박재형; 김광명; 권익찬; 김대덕
- Hyaluronic acid-ceramide; MRI; NIRF; Dual modality; Tumor targeting
- Issue Date
- Journal of controlled release
- VOL 162, NO 1, 111-118
- Hyaluronic acid-ceramide (HACE)-based nanoprobes for magnetic resonance (MR) and optical imaging were
developed for cancer diagnosis. Diethylenetriaminepentaacetic dianhydride (DTPA) was conjugated to HACE
for the chelation of gadolinium (Gd) as an MR contrast agent. Cy5.5 was also conjugated to the HACE backbone
as a near-infrared fluorescence (NIRF) imaging dye. The self-assembled HACE-based nanoprobe,
Cy5.5-HACE-DTPA-Gd, exhibited a uniformly distributed particle size and morphological shape. The HACEbased
nanoprobe did not induce serious cytotoxicity in U87-MG (low expression of CD44 receptor) and
SCC7 (high expression of CD44 receptor) cells. The cellular uptake efficiency of the HACE-based nanoprobe
was higher in SCC7 cells than in U87-MG cells, indicating an HA-CD44 receptor interaction. In vitro MR signal
enhancement of the HACE-based nanoprobe was confirmed compared with a commercial formulation (Magnevist).
Moreover, in vivo MR contrast enhancement of the HACE-based nanoprobe in the tumor region was
verified in an SCC7 tumor xenograft mouse model. The tumor targetability of the developed nanoprobe was
monitored by an NIRF imaging study, and improved accumulation of the nanoprobe in the tumor region was
observed. Therefore, this HACE-based dual-imaging nanoprobe can be used to make a more accurate diagnosis
of cancer based on its passive and active tumor targeting strategies.
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.